Barclays PLC Tenaya Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 269,464 shares of TNYA stock, worth $450,004. This represents 0.0% of its overall portfolio holdings.

Number of Shares

269,464

Previous 269,464 -0.0%

Holding current value

$450,004

Previous $520,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$1.93 - $3.99 $7,762 - $16,047	-4,022 Reduced 1.47%	269,464 $520,000
Q2 2024 Aug 14, 2024	SELL	$2.72 - $4.99 $1,433 - $2,629	-527 Reduced 0.19%	273,486 $848,000
Q1 2024 May 15, 2024	BUY	$2.88 - $6.8 $597,939 - $1.41 Million	207,618 Added 312.7%	274,013 $1.43 Million
Q4 2023 Feb 15, 2024	SELL	$1.73 - $3.39 $316,871 - $620,922	-183,163 Reduced 73.39%	66,395 $215,000
Q3 2023 Nov 07, 2023	BUY	$2.55 - $5.65 $613,111 - $1.36 Million	240,436 Added 2635.78%	249,558 $637,000
Q2 2023 Aug 03, 2023	SELL	$2.64 - $7.64 $55,115 - $159,500	-20,877 Reduced 69.59%	9,122 $54,000
Q1 2023 May 04, 2023	BUY	$1.92 - $3.59 $28,262 - $52,844	14,720 Added 96.34%	29,999 $85,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $3.19 $10,615 - $20,157	6,319 Added 70.52%	15,279 $31,000
Q3 2022 Nov 03, 2022	BUY	$2.9 - $5.88 $21,918 - $44,441	7,558 Added 539.09%	8,960 $26,000
Q2 2022 Aug 12, 2022	SELL	$5.01 - $14.12 $16,232 - $45,748	-3,240 Reduced 69.8%	1,402 $8,000
Q1 2022 May 16, 2022	BUY	$9.41 - $19.3 $43,681 - $89,590	4,642 New	4,642 $55,000

Others Institutions Holding TNYA

# of Institutions

Shares Held

56.3M

Call Options Held

900

Put Options Held

400

View Full List

About Tenaya Therapeutics, Inc.

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $69.1M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

More about TNYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account